T cell-mediated immunotherapy of metastases: state of the art in 2005

Bibliography

• SHANKARAN V IKEDA H, BRUCE AT et al.: IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 410(6832):1107–1111.
   Google Scholar
• ••A study about tumour incidence in RAG2-/-and STAT/- knock-out mice demonstrating the importance of these genes of the adaptive and innate immune system for the defence against spontaneous carcinomas.
   Google Scholar
• DARNELL RB, POSNER JB: Observing the invisible. Successful tumor immunity in human. Nat. Immunol (2003) 4:201.
   PubMed Web of Science ®Google Scholar
• PREUSS KD, ZWICK C, BORMAN C et al.: Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immuna Rev. (2002) 188:43–50.
   PubMed Web of Science ®Google Scholar
• BOON T, CERROTTINI J, VAN DEN EYNDE B et al.: Tumor antigens recognized by T lymphocytes. Annu. Rev. Immund. (1994) 12:337–365.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA: Progress in the development of immunotherapy for the treatment of patients with cancer. J. Intern. Med. (2001) 250:462–475.
   PubMed Web of Science ®Google Scholar
• JAGER E, JAGER D, KARBACH J et al: Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ES0-1-expressing melanoma. J. Exp. Med. (2000) 191:625–630.
   PubMed Web of Science ®Google Scholar
• FEUERER M, BECKHOVE P, BAT L et al.: Therapy of human tumors in NOD/SCID mice with patient derived re-activated memory T cells from bone marrow. Nat. Med. (2001) 7(4):452–458.
   PubMed Web of Science ®Google Scholar
• ••This study demonstrates the presence oftherapeutically active tumour-reactive memory T cells in the BM of many breast cancer patients. It provides evidence for regular spontaneous T cell responses against tumours in cancer patients and a 'proof of principle' that the spontaneously generated memory cells from BM can be re-activated and can transfer protective immunity in an autologous human tumour xenograft model.
   Google Scholar
• ROMERO P, PITTET MJ, ZIPPELIUS A et al.: T cells in tumor immunity. In: Cancer Immune Therapy: Current and Future Strategies. Stuhler G, Walden P (Eds), Wiley-VCH, Germany (2002):40–54.
   Google Scholar
• BECKHOVE P, FEUERER M, DOLENC M et al.: Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J. Clin. Invest. (2004) 114:67–76.
   PubMed Web of Science ®Google Scholar
• STARZL TE, ZINKERNAGEL RM: Antigen localization and migration in immunity and tolerance. N Engl. J. Med. (1998) 339:1905–1913.
   PubMed Web of Science ®Google Scholar
• MARINCOLA FM, JAFFEE EM, HICKLIN DJ et al.: Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol (2000) 74:181–273.
   PubMedGoogle Scholar
• GROH V, WU J, YEE C et al.: Tumour-derived soluble MIC ligands impair expression of NKG2D and cell activation. Nature (2002) 419(6908):734–738.
   PubMed Web of Science ®Google Scholar
• GABRILOVITCH DI: Production of vascular endothelial growth factor by human tumors inhibit the functional maturation of dendritic cells. Nat. Med. (1996) 2(10):1096–1103.
   PubMed Web of Science ®Google Scholar
• MUNN DH, SHARMA MD, HOU D et al.: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. (2004) 114:280–290.
   PubMed Web of Science ®Google Scholar
• ••This study illustrates how tumours canupregulate the enzyme IDO in a subset of APCs in tumour-draining lymph nodes, which leads to profound T cell anergy.
   Google Scholar
• DUNN GP, OLD LJ, SCHREIBER RD: The three Es of cancer immunoediting. Annu. Rev. Immunol (2004) 22:329–360.
   PubMed Web of Science ®Google Scholar
• BLATTMAN JN, GREENBERG PD: Cancer immunotherapy: a treatment for the masses. Science (2004) 305(9):200–205.
   PubMedGoogle Scholar
• NAIR SK, HEISER A, BOCZKOWSKI D et al.: Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomeras reverse transcriptase RNA transfected dendritic cells. Nat. Med. (2000) 6 (8) :1011–1017.
   PubMedGoogle Scholar
• RAMMENSEE H, BACHMANN J, EMMERICH NP et al.: Database for MHC ligands and peptide motifs. Immunogenetics (1999) 50:213–219.
   PubMed Web of Science ®Google Scholar
• HEISER A, COLEMAN D, DANNULL J et al.: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. (2002) 109:409–417.
   PubMed Web of Science ®Google Scholar
• SAEBOE-LARSSEN S, FOSSBERG E, GAUDERNACK G: mRNA-based eletrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). j Immunol (2002) 259:191–203.
   Google Scholar
• LUCAS ML, HELLER R: IL-12 therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma. DNA Cell Biol. (2003) 22(12):755–763.
   PubMed Web of Science ®Google Scholar
• MILLER G, LAHRS S, DEMATTEO RP: Overexpression of interleukin-12 enables dendritic cells to activate NK cells and confer systemic antitumor immunity. FASEB J. (2003) 17(0:728–730.
   PubMedGoogle Scholar
• SATOH Y, ESCHE C, BAMBOTTO A et al: Local administration of IL-12 transfected dendritic cells induces antitumor immune responses to colon adenocarinoma in the liver in mice. J. Exp. Ther. Oncol (2002) 2(6):337–349.
   PubMedGoogle Scholar
• STEVENSON FK, RICE J, ZHU D: Tumor vaccines. Adv. Immunol (2004) 82:49–103.
   PubMed Web of Science ®Google Scholar
• ••This is a profound review about DNAvaccines using predefined TAAs.
   Google Scholar
• CHLICHLIA K, SCHIRRMACHER V, SANDALTZOPOULOS R: Cancer immunotherapy: battling tumors with gene vaccines. In: Current Medical Chemistry - Anti-Inflammatory and Anti-Allergy Agents. (2005) (In Press).
   Google Scholar
• DONNELLY J, BERRY K, ULMER JB: Technical and regulatory hurdles for DNA vaccine. Int. J. Parasitol (2003) 33:457–467.
   PubMed Web of Science ®Google Scholar
• BERGMANN PJ, MCKNIGHT J, NOVOSAD A et al.: Long-term survival of dogs with advanced malignant melanoma after vaccination with xenogeneic human tyrosinase: a Phase I trial. Clin. Cancer Res. (2003) 9(4):1284–1290.
   PubMed Web of Science ®Google Scholar
• •This is an important 'proof of principle' study for xenogeneic DNA vaccination in a spontaneous aggressive animal neoplasm.
   Google Scholar
• TSO CL, ZISMAN A, PANTUCK A et ed.: Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res. (2001) 61(21):7925–2933.
   Google Scholar
• SCHIRRMACHER V: Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patients survival based on improved anti-tumor immune memory. Cancer Immunol Immunother. (2005) 54(6):587–598.
   PubMed Web of Science ®Google Scholar
• SCHIRRMACHER V, HAAS C, BONIFER R et al.: Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle Disease Virus. Gene Ther. (1999) 6:63–73.
   PubMed Web of Science ®Google Scholar
• SCHIRRMACHER V, AHLERT T, PROBSTLE T et al.: Immunization with virus modified tumor cells. Semin. Oncol. (1998) 25(6):677–696.
   PubMed Web of Science ®Google Scholar
• VIEWEG J, DANNULL J: Tumor vaccines: from gene therapy to dendritic cells - the emerging frontier. Urol Clin. North Am. (2003) 30(3):633–643.
   PubMed Web of Science ®Google Scholar
• SOIFFER R, HODI FS, HALUSKA F et al.: Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol (2003) 21(17):3343–3350.
   PubMed Web of Science ®Google Scholar
• PARDOLL D: T cells take aim at cancer. Proc. Natl Acad. Sci USA (2002) 99(25):15840–15842.
   PubMed Web of Science ®Google Scholar
• SLINGLUFF CUR, PETRONI GR, YAMSHCHIKOV GV et al.: Clinical and immunologic results of a randomized Phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin Oncol. (2003) 21:4016–4026.
   PubMed Web of Science ®Google Scholar
• HARRIS JE, RYAN L, HOOVER HC JR et al.: Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: eastern Cooperative oncology group study E5283. J. Clin. Oncol. (2000) 18(1):148–157.
   Google Scholar
• ASTSATUROV I, PETRELLA T, GAGRIACIK EU et al.: Amplification of virus-induced antimelanoma T-cell reactivity by high dose interferon-alpha2b: implications for cancer vaccines. Clin. Cancer Res. (2003) 9(12):4347–3455.
   PubMed Web of Science ®Google Scholar
• VAN DEN BROCKE LT, DASCHBACH E, THOMAS EK et al: Dendritic cell-induced activation of
   Google Scholar
• •• adaptive and innate antitumor immunity. Immunol (2003) 171(11):5842–5852.
   Google Scholar
• LAM JS, BELLDEGRUN AS, FIGLIN RA: Advances in immune-based therapies of renal cell carcinoma. Expert Rev. Anticancer Ther. (2004) 4(6):1081–1096.
   PubMedGoogle Scholar
• DILLMAN RO, WIEMANN M, NAYAK SK et al.: Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized Phase II trial of the cancer biotherapy research group. J. Immunother. (2003) 26(4):367–373.
   PubMed Web of Science ®Google Scholar
• VAISHAMPAYAN U, ABRAMS J, DARRAH D et al.: Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin. Cancer Res. (2002) 8(12):3696–3701.
   PubMed Web of Science ®Google Scholar
• DRANOFF G, JAFFEE E, LAZENBY Aet al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA (1993) 90:3539–3543.
   Google Scholar
• GRI G, GALLO E, DICARLO E et al.: 0X40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response. J. Immunol (2003) 170(1):99–106.
   PubMed Web of Science ®Google Scholar
• PHAN GQ, YANG JC, SHERRY RM et al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte associated antigen 4 blockade in patients with metastatic melanoma. Proc. Nail. Acad. Sci USA (2003) 100(14):8372–8377.
   PubMed Web of Science ®Google Scholar
• JOCHAM D, RICHTER A, HOFFMANN L et al.: Adjuvant autologous renal tumor cell vaccine and risk of tumor progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet (2004) 363:594.
   PubMed Web of Science ®Google Scholar
• CASSEL WA, MURRAY DR, OLKOWSKI ZL: Newcastle disease virus oncolysate in the management of stage III malignant melanoma. In: Viral Therapy of Human Cancer. Sinkovics JG, Horvath JC (Eds), Marcel Dekker, New York, USA (2005):677–689.
   Google Scholar
• BYSTRYN JC, ZELENIUCH-JACQUOTTE A, ORATZ R et al.: Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin. Cancer Res. (2001) 8:1882–1887.
   Google Scholar
• ANDRE F, ESCUDIER B, ANGEVIN E et al.: Exosomes for cancer immunotherapy. Ann. Oncol (2004) 15\(Suppl. 4):141–144.
   Google Scholar
• WALDEN P, STUHLER G, TREFZER U: Hybrid cell vaccination for cancer immune therapy. In: Cancer Immune Therapy: Current and Future Strategies. Stuhler G, Walden P (Eds), Wiley-VCH, Germany (2002):230–250.
   Google Scholar
• LINDNER M, SCHIRRMACHER V: Tumor cell dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols. Eur. j Clin. Invest. (2002) 32:207–217.
   PubMed Web of Science ®Google Scholar
• KJAERGAARD J, SHIMIZU K, SHU S: Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell. Immunol. (2003) 225(2):65–74.
   PubMed Web of Science ®Google Scholar
• •This study describes large-scale electrofusion techniques for generating DC-tumour hybrids as cancer vaccines. In a mouse sarcoma, a single therapeutic vaccination with hybrid vaccine using autolougous but not allogeneic DCs caused eradication of established metastases.
   Google Scholar
• SRIVASTAVA PK, MENORETT A, BASU S et al.: Heat-shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity (1998) 8:657–665.
   PubMed Web of Science ®Google Scholar
• LEWIS JJ: Therapeutic cancer vaccines: using unique antigens.. Proc. Natl Acad. Sci. USA (2004) 101\(Suppl. 2):14653–14656.
   Google Scholar
• •An important review concerning the theory behind the use of autologous 'unique' TAAs and summarising the state of the art of clinical studies with gp96 HSP peptide complexes (HSPPC–96).
   Google Scholar
• WANG XY, KAZIM L, REPASKY EA et al.: Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8* T-cell responses and reduces pulmonary metastatic disease. Int. J. Cancer (2003) 105(2):226–231.
   PubMed Web of Science ®Google Scholar
• GAULT U: Autologous tumor vaccines processed to express a-gal epitopes: a practical approach to immunotherapy in cancer. Cancer Immunol Immunother. (2004) 53:935–945.
   PubMed Web of Science ®Google Scholar
• SCHIRRMACHER V BOSSLET K, SHANTZ G et al.: Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes. Int. J. Cancer (1979) 23:245–252.
   Google Scholar
• SCHIRRMACHER V FOGEL M, RUSSMANN E et al.: Antigenic variation in cancer metastasis. Immune escape versus immune control. Cancer Metastasis Rev. (1982) 1:241–274.
   Google Scholar
• SO T, TAKENOYAMA M, ICHIKI Y et al.: A different pattern of cytotoxic T lymphocyte recognition against primary and metastatic tumor cells in a patient with nonsmall cell lung carcinoma. Cancer (2005) 1(103):200–208.
   Google Scholar
• SCHIRRMACHER V MOERKOSTER S, BUCUR M et al.: Breaking tolerance to a tumor-associated viral superantigen as a basis for graft-versus-leukemia reactivity. Int. J. Cancer (2000) 87:695–706.
   PubMed Web of Science ®Google Scholar
• TANG X, YOKUM DE, DEJONGE D et al.: Increased activation-induced cell death in peripheral lymphocytes of rheumatoid arthritis patients: the mechanism of action. Immunology (2004) 112:496–505.
   PubMed Web of Science ®Google Scholar
• KRIEG AM: CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol (2002) 20:709–760.
   PubMed Web of Science ®Google Scholar
• LEITNER WW, HWANG LN, DEVEER MJ et al.: Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. (2003) 9:33-39. A nice example of how to break immunological tolerance by introducing 'danger signals' via an alphavirus-based DNA vaccine, thus activating innate immune responses and host APCs.
   Google Scholar
• SCHIRRMACHER V, FORG P, DALEMANS Wet al.: Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine. Gene Ther. (2000) 7:1137–1147.
   Google Scholar
• PARDOLL D: Does the immune system see tumors as foreign or self? Annu. Rev. Immunol (2003) 12:807–839.
   Google Scholar
• WASHBURN B, SCHIRRMACHER V: Human tumor cell infection by Newcastle disease virus leads up to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int. J. Oncol (2002) 21:85–93.
   PubMed Web of Science ®Google Scholar
• HUANG TH, WU PY, LEE CN et al.: Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen. Blood (2000) 96:3663–3670.
   PubMed Web of Science ®Google Scholar
• YOU Z, HUANG X, HESTER J et al: Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res. (2001) 61:3704–3711.
   PubMed Web of Science ®Google Scholar
• HUNG CF, CHENG WF, CHAT CY et aL:Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J. Immunol (2001) 166:5733–5740.
   PubMed Web of Science ®Google Scholar
• KIM JJ, TRIVEDI NN, WILSON DM et al.: Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. Oncogene (1998) 17:3125–3135.
   PubMed Web of Science ®Google Scholar
• IRVINE KR, CHAMBERLAIN RS, SHULMAN EP et al.: Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimes that use two different vectors. J. Natl. Cancer Inst. (1997) 89:1595–1601.
   PubMed Web of Science ®Google Scholar
• MENG WS, BUTTERFIELD LH, RIBAS A et al.: Alpha-Fetoprotein-specific tumor immunity induced by plasmid prime adenovirus boost genetic vaccination. Cancer Res. (2001) 61:8782–8786.
   PubMed Web of Science ®Google Scholar
• MAHNKE Y, SCHIRRMACHER V: A novel tumor model sytem for the study of long-term protective immunity and immune T cell memory. Cell. Immunol (2003) 221:89.
   PubMed Web of Science ®Google Scholar
• MAHNKE Y, SCHIRRMACHER V: Characteristics of a potent tumor vaccine-induced secondary anti-tumor T cell response. Int. j Oncol (2004) 24:1427.
   PubMed Web of Science ®Google Scholar
• MAHNKE YD, SCHWENDEMANN J, BECKHOVE P, SCHIRRMACHER V: Maintenance of long-term tumour-specific T-cell memory by residual dormant tumor cells. Immunology (2005) 115:325–336.
   PubMed Web of Science ®Google Scholar
• ••This study suggests that persistance ofTAAs from residual dormant tumour cells after successful therapy is important and is implicated in the maintenance of long-term tumour-specific T cell memory.
   Google Scholar
• HAAS C, LULEI M, FOURNIER P et al.: T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine. Vaccine (2005) 23(19):2439–2453.
   PubMed Web of Science ®Google Scholar
• HAAS C, STRAUSS G, MOLDENHAUER G, IORIO RM, SCHIRRMACHER V: Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine. Clin. Cancer Res. (1998) 4:721–730.
   PubMed Web of Science ®Google Scholar
• GALLUCCI S, MATZINGER P: Danger signals: SOS to the immune system. Curr. Opin. Immunol. (2001) 13:114.
   PubMed Web of Science ®Google Scholar
• ••This is a 'classical' review about danger signals and their importance for immune responses.
   Google Scholar
• TERMEER CC, SCHIRRMACHER V, BROCKER EB et al.: Newcastle disease virus infection induces B7-1/B7-2 independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther. (2000) 7:316.
   PubMed Web of Science ®Google Scholar
• VON HOEGEN P, WEBER E, SCHIRRMACHER V: Modification of tumor cells by a low dose of Newcastle disease virus; augmentation of the tumor-specific T cell response in the absence of an anti-viral response. Eur. j Immunol (1988) 18:1159–1166.
   PubMed Web of Science ®Google Scholar
• ERTEL C, MILLAR NS, EMMERSON PT et al.: Viral hemagglutinin augments peptide specific cytotoxic T-cell responses. Eur. j Immunol (1993) 23:2592.
   PubMed Web of Science ®Google Scholar
• MOINGEON P, DETAISNE C, ALMOND J: Delivery technologies for human vaccines. Br. Med. Bull. (2002) 62:29–44.
   PubMed Web of Science ®Google Scholar
• ZHU MZ, MARSHALL J, COLE D et al: Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin. Cancer Res. (2000) 6:24–33.
   PubMed Web of Science ®Google Scholar
• RAYNER JO, DRYGA SA, KAMRUD KI: Alphavirus vectors and vaccination. Rev. Med. Virol (2002) 12:279–296.
   PubMed Web of Science ®Google Scholar
• SINKOVICS JG: Progressive development of viral therapy of human cancers: a personal narrative account. In: Viral Therapy of Human Cancers. Sinkovics JG, Horvath JC (Eds), Marcel Dekker, New York, USA (2005):1–148.
   Google Scholar
• SCHIRRMACHER V: Antitumor immune memory and its activation for control of residual tumor cells and improvement of patient survival: A new concept derived from translational research with the virus-modified tumor vaccine ATV-NDV. In: Viral Therapy of Human Cancers. Sinkovics JG, Horvath JC (Eds), Marcel Dekker, New York, USA (2005):481–531.
   Google Scholar
• STOJDL DF, LICHTY BD, TENOEVER BR et al.: VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 4:263–275.
   PubMed Web of Science ®Google Scholar
• YANG WQ, SENGER DL, LUN XQ et al.: Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. Gene Ther. (2004) 11(21):1579–1589.
   PubMed Web of Science ®Google Scholar
• WILDNER O: Comparison of replication-selective, oncolytic viruses for the treatment of human cancers. Curr. Opin. Mol Ther. (2003) 5(4):351–361.
   PubMed Web of Science ®Google Scholar
• EVERTS B, VAN DER POEL HG: Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. (2005) 12(2):141–161. [Erratum in: Cancer Gene Ther. (2005) 12(4):438].
   Google Scholar
• LORENCE RM, ROBERTS MS, GROENE WS et al.: Replication-competent, oncolytic Newcastle disease virus for cancer therapy. In: Replication-Competent Viruses for Cancer Therapy Monograph Virology. Vol. 22. Herndiz Driever P, Rabkin SD (Eds), Karger, Basel, Switzerland (2001):160–182.
   Google Scholar
• •This is a comprehensive review about the biology of a relevant replication-competent oncolytic virus.
   Google Scholar
• PECORA AL, RIZVI N, COHEN GI et al.: Phase I trial of intravenous administration of PV 701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol (2002) 20:2251–2266.
   PubMed Web of Science ®Google Scholar
• •This clinical study demonstrates that replication-competent, oncolytic NDV is well-tolerated in humans in systemic doses of at least 3 x 109 infectious units.
   Google Scholar
• HORVATH JC: Newcastle disease virus: its oncolytic properties. In: Viral Therapy of Human Cancer. Sinkovics JG, Horvath JC (Eds), Marcel Dekker, New York, USA (2005):533–574.
   Google Scholar
• FU X, NAKAMORI M, ZHANG X: Fusogenic oncolytic herpes simplex viruses for therapy of solid tumors. In: Viral Therapy of Human Cancer. Sinkovics JG, Horvath JC (Eds), Marcel Dekker, New York, USA (2005):713–738.
   Google Scholar
• MCCORMICK F: Oncolytic viruses that depend on loss of RB or p53. In: Viral Therapy of Human Cancer. Sinkovics JG, Horvath JC (Eds), Marcel Dekker, New York, USA (2005):781–795.
   Google Scholar
• KIRN D, MARTUZA RL, ZWIEBEL J: Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med. (2001) 7:781–787.
   PubMed Web of Science ®Google Scholar
• KHURI FR, NEMUNAITIS J, GANLY I et al.: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-Fluorouracil in patients with recurrent head and neck cancer. Nat. Med. (2000) 6:879–885.
   PubMed Web of Science ®Google Scholar
• REED JC, WILSON DB: Cancer immunotherapy targeting survivin. Clin. Cancer Res. (2003) 9:6310–6315.
   PubMed Web of Science ®Google Scholar
• HEICAPPELL R, SCHIRRMACHER V, VON HOEGEN P et al.: Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. Int. J. Cancer (1986) 37:569–577.
   Google Scholar
• SCHILD H, VON HOEGEN P, SCHIRRMACHER V: Modification of tumor cells by a low dose of Newcastle disease virus: II. Augmented tumor specific T cell response as a result of CD4* and CD8* immune T cell cooperation. Cancer Immunol Immunother. (1988) 28:22–28.
   Google Scholar
• VON HOEGEN P, WEBER E, SCHIRRMACHER V: Modification of tumor cells by a low dose of Newcastle disease virus; augmentation of the tumor-specific T cell response in the absence of an anti-viral response. Eur. j Immunol (1988) 18:1159–1166.
   PubMed Web of Science ®Google Scholar
• FOURNIER P, ZENG J, SCHIRRMACHER V: Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-a responses by viral protein or dsRNA. Int. J. Oncol (2003) 23:673–680.
   PubMed Web of Science ®Google Scholar
• ZENG J, FOURNIER P, SCHIRRMACHER V: Induction of interferon a and tumor necrosis factor-related apoptosis-inducing blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology (2002) 297:19–30.
   PubMed Web of Science ®Google Scholar
• ZENG J, FOURNIER P, SCHIRRMACHER V: Stimulation of human natural interferon-a response via paramyxo-virus hemagglutinin lectin-cell interaction. J. Mo/. Med. (2002) 80:443–451.
   PubMed Web of Science ®Google Scholar
• SCHIRRMACHER V HEICAPPELL R: Prevention of metastatic spread by postperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity. Clin. Exp. Metastasis (1987) 5(2):147–156.
   PubMed Web of Science ®Google Scholar
• PLAKSIN D, PROGADOR A, VADAI E et al.: Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV). Int. J. Cancer (1994) 59:796–801.
   PubMed Web of Science ®Google Scholar
• SHOHAM J, HIRSCH R, ZAKAY-RONES Z et al.: Augmentation of tumor cell immunogenicity by viruses- an approach to specific immunotherapy of cancer. Nat. Immun. (1990) 9:166–205.
   Google Scholar
• BIER H, ARMONAT G, BIER J et al.: Postoperative active-specific immunotherapy of lymph node micrometastasis in a Guinea pig tumor model. Otorhinopharyngology (1989) 51:197–205.
   Google Scholar
• OKAJI Y, TSUNO NH, KITAYAMA J et al.: Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci. (2004) 95(1):85–90.
   PubMed Web of Science ®Google Scholar
• NIETHAMMER AG, XIANG R, BECKER JC et al: A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. (2002) 8(12):1369–1375.
   PubMed Web of Science ®Google Scholar
• LI Y, WANG MN, LI H et al.: Active immunization against the vascular endothelial growth factor receptor flkl inhibits tumor angiogenesis and metastasis. J. Exp. Med. (2002) 195(12):1575–1584.
   PubMed Web of Science ®Google Scholar
• WATERSTON AM, SALWAY F, ANDREAKOS E et al.: TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model. Br. J. Cancer (2004) 90(6):1279–1284.
   PubMed Web of Science ®Google Scholar
• SCHIRRMACHER V, VON HOEGEN P: Importance of tumor cell membrane integrity and viability for CTL activation by cancer vaccines. Vaccine Res. (1993) 2:183.
   Google Scholar
• AHLERT T, SAUERBREI W, BASTERT G et al.: Tumor cell number and viability as quality and efficacy parameters of autologous virus modified cancer vaccines./ Clin. Oncol (1997) 15:1354.
   PubMed Web of Science ®Google Scholar
• KAECH SM, WHERRY EJ, AHMED R: Effector and memory T cell differentiation: implications for vaccine development. Nat. Rev. (2002) 2:251.
   Google Scholar
• •An expert review about memory T cell differentiation, open questions and implications for vaccine development.
   Google Scholar
• VEIGA-FERNANDES H, WALTER U, BOURGEOIS C et al.: Response of naïve and memory CD8+ T cells to antigen stimulation in vivo. Nat. Immunol (2000) 1:47.
   PubMed Web of Science ®Google Scholar
• VERMORKEN JB, CLAESSEN AM, VAN TINTEREN H et al.: Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial. Lancet (1999) 353:345.
   Google Scholar
• ••The first report about a randomisedclinical trial of ASI. This is of importance because it uses an autologous live cell vaccine and because it shows a clinical benefit.
   Google Scholar
• LIANG W WANG H, SUN TM et al.: Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J. Gastroenterol (2003) 9(3):495.
   Google Scholar
• BERD D, SATO T, MAGUIRE H JR et al: Immunopharmacologic analysis of an autologous hapten-modified human melanoma vaccine. J. Clin. Oncol (2003) 22(3):403–415.
   PubMed Web of Science ®Google Scholar
• O'ROURKE MG, JOHNSON M, LANAGAN C et al: Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immunother. (2003) 52:387–395.
   PubMed Web of Science ®Google Scholar
• SCHIRRMACHER V FEUERER M, BECKHOVE P et al: T cell memory, anergy and immunotherapy in breast cancer. J. Mammary Gland Biol. Neoplasia (2002) 7(2):201–208.
   PubMed Web of Science ®Google Scholar
• KARCHER J, DYCKHOFF G, BECKHOVE P et al.: Anti-tumor vaccination with HNSCC with autologous virus-modified tumor cells. Cancer Res. (2004) 64(21):8057–8061.
   PubMed Web of Science ®Google Scholar
• STEINER HH, BONSANTO MM, BECKHOVE P et al.: Anti-tumor vaccination of patients with glioblastoma multiforme in a case-control study: feasibility, safety and clinical benefit. Clin. Oncol (2004) 22(21):4272–4281.
   Web of Science ®Google Scholar
• ••A case-control study in glioblastomapatients demonstrating autologous vaccine-induced memory T cell responses and clinical benefit; perhaps the best survival data in this most devastating type of cancer.
   Google Scholar
• BENDANDI M, GOCKE CD, KOBRIN CB et al.: Complete molecular remission induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. (1999) 5(10):1171–1177.
   PubMed Web of Science ®Google Scholar
• TIMMERMANN JM et al.: Idiotype-pulsed dendritic cell vaccination lymphoma: clinical and immune responses in 35 patients. Blood (2002) 99:1517–1526.
   PubMed Web of Science ®Google Scholar
• TIMMERMAN JM: Immunotherapy for lymphomas. Int. J. HematoL (2003) 77(5):444–455.
   PubMed Web of Science ®Google Scholar
• MOCELLIN S et al.: Part I: Vaccines for solid tumours. Lancet Oncol. (2004) 5:681–689.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA et aL: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. (2004) 10:909–915.
   PubMed Web of Science ®Google Scholar
• MCCUNE CS, O& DONNELL RW, MARQUIS DM et aL: Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Immunother. (1990) 32:62.
   PubMed Web of Science ®Google Scholar
• ORATZ R, COCKERILL C, SPEYER J et aL: Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine. J. Biol. Response Mod. (1989) 8:355–358.
   PubMedGoogle Scholar
• SCHIRRMACHER V, BECKHOVE P, KROGER A et aL: Effective immune rejection of advanced metastasized cancer. Int. J. Oncol. (1995) 6:505-521. An important predinical GvL study demonstrating the effectiveness of ADI with special immune T cells from a tumour-resistant MHC identical mouse strain in advanced metastasised cancer, a stage that is normally resistant to therapy. There are only a few successful reports in such advanced disease. The study also introduces new non-invasive procedures, such as 31P-NMR spectroscopy of primary tumours and 1-14-NMR imaging of liver metastases, to follow the therapy effects in individual mice over time.
   Google Scholar
• MUERKOSTER S, ROCHA M, CROCKER PR et aL: Sialoacihesin-positive host macrophages play an essential role in graft versus leukemia (GvL) reactivity in mice. Blood (1999) 93(12):4375–4386.
   PubMed Web of Science ®Google Scholar
• MOERKOSTER S et al.: GvL reactivity involves cluster formation between superantigen-reactive donor T-lymphocytes and host macrophages. Clin. Cancer Res. (1998) 4:3095–3106.
   PubMed Web of Science ®Google Scholar
• ROCHA M, UMANSKY V, LEE KH et ell.: Differences between graft-versus-leukemia (GvL) and graft-versus-host (GvH) reactivity. I. Interaction of donor immune T cells with tumor and/or host cells. Blood (1997) 6:2189–2202.
   Google Scholar
• FICHTNER KP, SCHIRRMACHER V, GRIESBACH A et al.: In vivo1H-NMR microimaging with respiratory triggering for monitoring adoptive immunotherapy of metastatic mouse lymphoma. Magn. Reson. Med. (1997) 38:440–455.
   PubMed Web of Science ®Google Scholar
• MELIEF CJ: Regulation of cytotoxic T lymphocyte responses by dendritic cells. Peaceful coexistence of cross-priming and direct priming? Eur. j ImmunoL (2003) 33:2645–2654.
   Google Scholar
• SCHIRRMACHER V FEUERER M, FOURNIER P et al.: T cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. Trends Molec. Med. (2003) 9:526–534.
   PubMed Web of Science ®Google Scholar
• GALEA-LAURI J, WELLS JW DARLING D et al.: Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer ImmunoL Immunother. (2004) 53:963–977.
   Google Scholar
• LOHOFF M, MAX TW: Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat. Rev. ImmunoL (2005) 5:125–135.
   PubMed Web of Science ®Google Scholar
• SCHIRRMACHER V GRIESBACH A, GEHRING M et al.: Genetic separation of GvL and GvH reactivity in new recombinant-inbred tumor-resistant mouse strains. Int. J. Oncol. (1996) 8:1035–1044.
   PubMed Web of Science ®Google Scholar
• LEEK, HACKER HJ, UMANSKY V et al.: Changes in liver glycogen and lipid metabolism during transient raft-versus-host (GvH) and graft-versus-leukemia (GvL) reactivity. Int. J. Oncol. (1996) 9:635–643.
   PubMed Web of Science ®Google Scholar
• SCHIRRMACHER V, MOERKOSTER S, UMANSKY V: Antagonistic effects of systemic IL-2 on immune T cell mediated graft-versus-leukemia (GvL) reactivity. Clin. Cancer Res. (1998) 4:2635–2645.
   PubMed Web of Science ®Google Scholar
• MOERKOSTER S, LAMAN JD, ROCHA M et al.: Functional and in situ evidence for nitric oxide production driven by CD40 - CD4OL interactions in graft-versus-leukemia-reactivity. Clin. Cancer Res. (2000) 16:1988–1996.
   Google Scholar
• FEUERER M, BECKHOVE P, GARBI N et al.: Bone marrow as a priming site for T cell responses to blood-borne antigen. Nat. Med. (2003) 9:1151-1157. This study provides evidence that a primary lymphoid organ, such as the BM, can initiate T cell immune responses and, thus, perform secondary immune functions. It questions a dogma of textbook immunology, which associates primary and secondary immune functions with distinct organs.
   Google Scholar
• FEUERER M, BECKHOVE P, MAHNKE Y et al.: Bone marrow microenvironment facilitating dendritic cell - CD4 T cell interactions and maintenance of CD4 memory. Int. J. Oncol. (2004) 25:867–876.
   PubMed Web of Science ®Google Scholar
• BM L, BECKHOVE P, FEUERER M et al.: Cognate interactions between memory T cells and tumor antigen presenting dendritic cells from bone marrow of breast cancer patients: bi-directional cell stimulation survival and anti-tumor activity in vivo. Int. J. Cancer (2003) 103:73–83.
   PubMed Web of Science ®Google Scholar
• KHAZAIE K, PRIFTI S, BECKHOVE P et aL: Persistence of dormant tumor cells in the bone marrow of tumor-cell-vaccinated mice correlates with long term immunological protection. Proc. Natl. Acad. Sci. USA (1994) 91:7430.
   PubMed Web of Science ®Google Scholar
• MOLLER M, GOUNARI F, PRIFTI S et aL: Eb-lacZ tumor dormancy in bone marrow and lymph nodes: active control of proliferating tumor cells by CD8+ immune T cells. Cancer Res. (1998) 58:5439.
   PubMed Web of Science ®Google Scholar
• FEUERER M, ROCHA M, BAIL et aL: Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int. J. Cancer (2001) 92(1):96.
   PubMed Web of Science ®Google Scholar
• ZENG D, HOFFMANN P, LAN F et aL: Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact on allogeneic bone marrow transplantation. Blood (2002) 99:1449–1457.
   PubMed Web of Science ®Google Scholar
• MAZO IB, HONCZARENKO M, LEUNG H et aL: Bone marrow is a major reservoir and site of recruitment for central memory CD8* T cells. Immunity (2005) 22:259–270.
   PubMed Web of Science ®Google Scholar
• BECKER TC, COLEY SM, WHERRY EJ et aL: Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J. ImmunoL (2005) 174:1269–1273.
   PubMed Web of Science ®Google Scholar
• GRIGG A, RITCHIE D: Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. BioL Blood Marrow Transplant. (2004) 10:579–590.
   PubMed Web of Science ®Google Scholar
• MUTIS T: Targeting alloreactive donor T-cells to hematopoietic system-restricted minor histocompatibility antigens to dissect graft-versus-leukemia effects from graft-versus-host disease after allogeneic stem cell transplantation. Int. J. Hematol (2003) 78:208–212.
   PubMed Web of Science ®Google Scholar
• DEEG HJ: New strategies for prevention and treatment of graft-versus-host disease and for induction of graft-versus-leukemia effects. Int. J. Hematol (2003) 77:15–21.
   PubMed Web of Science ®Google Scholar
• REZVANI K, GRUBE M, BRENCHLEY JM et al.: Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood (2003) 102:2892–2900.
   PubMed Web of Science ®Google Scholar
• RIDDELL SR, MURATA M, BRYANT Set al.: Minor histocompatibility antigens-targets of graft versus leukemia responses. Int. J. Hematol (2002) 76(Suppl. II):155–161.
   Google Scholar
• MOLLDREM J, DERMIME S, PARKER K et al: Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Need (1996) 88:2450–2457.
   Google Scholar
• GAO L, BELLANTUONO I, ELSASSER A et al: Selective elimination of leukemic CD23(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood (2000) 95:2198–2203.
   PubMed Web of Science ®Google Scholar
• OSMAN Y, TAKAHASHI M, ZHENG Z et al: Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia (1999) 13:166–174.
   PubMed Web of Science ®Google Scholar
• WALTER EA, GREENBERG PD, GILBERT MJ et al.: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl. J. Med. (1995) 333:1038–1044.
   PubMed Web of Science ®Google Scholar
• HESLOP HE, NG CY, LI C et al: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. (1998) 2:551–555.
   Web of Science ®Google Scholar
• ROONEY CM, SMITH CA, NG CY et al: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood (1998) 92:1549–1555.
   PubMed Web of Science ®Google Scholar
• ZORN E, WANG KS, HOCHBERG EP et al.: Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin. Cancer Res. (2002) 8:2052–2060.
   PubMed Web of Science ®Google Scholar
• DUDLEY ME, ROSENBERG SA: Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer (2003) 3(9):666–675.
   PubMed Web of Science ®Google Scholar
• ••A clinical ADI study combined withlymphodepletion demonstrating effectiveness in patients with solid metastatic tumours. As in [130], lymphodepletion is part of the therapy success. It probably causes impairment of T regulatory cells, eliminates 'sinks' for homeostatic cytokines and causes tumour necrosis in conjunction with APC activation.
   Google Scholar
• CHEEVER MA et al: Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J. Exp. Med. (1982) 155:968–980.
   PubMed Web of Science ®Google Scholar
• OVERWIJK WW et al: Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. (2003) 198:569–580.
   PubMed Web of Science ®Google Scholar
• YEE C et al.: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA (2002) 99:16168–16173.
   PubMed Web of Science ®Google Scholar
• DUDLEY ME et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298:850–854.
   PubMed Web of Science ®Google Scholar
• KLEBANOFF CA. KHONG H, ANTONY PA et al: Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol (2005) 26(2):111–117.
   PubMed Web of Science ®Google Scholar
• SAKAGUCHI S: Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol (2004) 22:531–562.
   PubMed Web of Science ®Google Scholar
• •Am important review about T regulatory cells and their role in the maintenance of self-tolerance.
   Google Scholar
• P1-JAN GQ et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci USA (2003) 100:8372–8377.
   PubMed Web of Science ®Google Scholar
• ALPDOGAN O, VAN DEN BRINK MR: IL-7 and IL-15: therapeutic cytokines for immunodeficiency. Trends Immunol (2005) 26:56–64.
   PubMed Web of Science ®Google Scholar
• PINTHUS JH, ESHHAR Z: The T-body approach: towards cancer immuno-gene therapy. In: Cancer Immune Therapy: Current and Future Strategies. Stuhler G, Walden P (Eds), Wiley-VCH, Germany (2002):287–298.
   Google Scholar
• FRIEDMANN-MORVINSKI D, BENDAVID A. WAKS T, SCHINDLER D, ESHHAR Z: Redirected primary T-cells harbouring a chimeric receptor require costimulation for their antigen-specific activation. Blood (2005)105(12):3087–3093.
   Google Scholar
• PINTHUS JH, WAKS T, MAUNA V et al: Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J. Clin. Invest. (2004) 114(12):1774–1781.
   PubMed Web of Science ®Google Scholar
• REUSCH U, LE GALL F, HENSEL M et al: Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells. Int. J. Cancer (2004) 112:509–518.
   PubMed Web of Science ®Google Scholar
• GANSS R, ARNOLD B, HAMMERLING GJ: Mini-review: Overcoming tumor-instrinsic resistance to immune effector function. Eur. J. Immunol (2004) 34:2635–2641.
   PubMed Web of Science ®Google Scholar
• GARBI N, ARNOLD B, GORDON S et al: CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. Immunol (2004) 172:5861–5869.
   Web of Science ®Google Scholar
• HADDAD JJ, HARB HL: Cyokines and the regulation of hypoxia-inducible factor (HIF)-1a. Int. Immunopharmacol. (2005) 5:461–483.
   PubMed Web of Science ®Google Scholar
• ZARDI EM, ZARDI DM, CACCIAPIAGLIA F et al: Review. Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs. Int. Immunopharmacol (2005) 5:437–459.
   Google Scholar
• SCHIRRMACHER V, SHANTZ G, CLAUER G et al.: Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastases formation in vivo. Int. J. Cancer (1979) 23:233–244.
   Web of Science ®Google Scholar
• SCHIRRMACHER V, CHEINGSONG-POPOV R, ARNHEITER H: Hepatocyte-tumor cell interaction in vitro. I. Conditions for rosette formation and inhibition by anti H-2 antibody. J. Exp. Med. (1980) 151:984–989.
   Google Scholar
• SPRINGER GF, CHEINGSONG-POPOV R, SCHIRRMACHER Vet al.: Proposed molecular basis of murine tumor cell-hepatocyte interaction. J. Biol. Chem. (1983) 258:5702–5706.
   Google Scholar
• UMANSKY V, ROCHA M, SCHIRRMACHER V: Liver endothelial cells: participation in host response to lymphoma metastasis. Cancer Metastasis Rev. (1996) 15:273–279.
   PubMed Web of Science ®Google Scholar
• LILIENSIEK B, ROCHA M, UMANSKY Vet al.: Identification of 4 genes in endothelial cells whose expression is affected by tumor cells and host immune status — a study in ex vivo isolated endothelial cells. Blood (1998) 92:3394–3404.
   Google Scholar
• SCHIRRMACHER V: Cancer metastasis: experimental approaches, theoretical concepts and impacts for treatment strategies. Adv. Cancer Res. (1985) 43:1–73.
   PubMed Web of Science ®Google Scholar
• SCHIRRMACHER V, LEIDIG S, GRIESBACH A: In situ activation of syngeneic tumor specific cytotoxic T-lymphocytes: importance of site of antigen stimulation. Cancer Immunol Immunother. (1991) 33:299–306.
   PubMedGoogle Scholar
• FORG P, VON HOEGEN P, SCHIRRMACHER V: Superiority of the ear pinna over muscle tissue as site for DNA vaccination. Gene Ther. (1998) 5:789–797.
   PubMed Web of Science ®Google Scholar
• JURIANZ K, VON HOEGEN P, SCHIRRMACHER V: Superiority of the ear pinna over a subcutaneous tumor inoculation site for induction of a TH1 type cytokine response. Cancer Immunol Immunother. (1998) 45:327–333.
   PubMed Web of Science ®Google Scholar
• SCHIRRMACHER V: T cell immunity in the induction and maintenance of a tumor dormant state. Semin. Cancer Biol. (2001) 11:285.
   PubMed Web of Science ®Google Scholar
• MCCOY JL, RUCKER R, PETROS JA: Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade, or lymph node status. Breast Cancer Res. (2000) 60:227–234.
   Web of Science ®Google Scholar